Literature DB >> 34345443

Perioperative dual antiplatelet therapy for patients undergoing spine surgery soon after drug eluting stent placement.

Sophie M Peeters1, Daniel Nagasawa2, Bilwaj Gaonkar1, Tianyi Niu3, Alexander Tucker4, Mark Attiah1, Diana Babayan1, Natalie Moreland5, Isaac Yang1, Marcela Calfon Press6, Luke Macyszyn1.   

Abstract

BACKGROUND: Performing emergent spinal surgery within 6 months of percutaneous placement of drug-eluting coronary stent (DES) is complex. The risks of spinal bleeding in a "closed space" must be compared with the risks of stent thrombosis or major cardiac event from dual antiplatelet therapy (DAPT) interruption.
METHODS: Eighty relevant English language papers published in PubMed were reviewed in detail.
RESULTS: Variables considered regarding surgery in patients on DAPT for DES included: (1) surgical indications, (2) percutaneous cardiac intervention (PCI) type (balloon angioplasty vs. stenting), (3) stent type (drug-eluting vs. balloon mechanical stent), and (4) PCI to noncardiac surgery interval. The highest complication rate was observed within 6 weeks of stent placement, this corresponds to the endothelialization phase. Few studies document how to manage patients with critical spinal disease warranting operative intervention within 6 months of their PCI for DES placement.
CONCLUSION: The treatment of patients requiring urgent or emergent spinal surgery within 6 months of undergoing a PCI for DES placement is challenging. As early interruption of DAPT may have catastrophic consequences, we hereby proposed a novel protocol involving stopping clopidogrel 5 days before and aspirin 3 days before spinal surgery, and bridging the interval with a reversible P2Y12 inhibitor until surgery. Moreover, postoperatively, aspirin could be started on postoperative day 1 and clopidogrel on day 2. Nevertheless, this treatment strategy may not be appropriate for all patients, and multidisciplinary approval of perioperative antiplatelet therapy management protocols is essential. Copyright:
© 2021 Surgical Neurology International.

Entities:  

Keywords:  Cangrelor; Drug-eluting stent; Dual antiplatelet therapy; Emergent spine surgery; P2Y12 inhibitor

Year:  2021        PMID: 34345443      PMCID: PMC8326059          DOI: 10.25259/SNI_337_2021

Source DB:  PubMed          Journal:  Surg Neurol Int        ISSN: 2152-7806


INTRODUCTION

At least 6–12 months of dual antiplatelet therapy (DAPT) are routinely utilized after placement of drug-eluting coronary stents (DES).[7] For patients requiring urgent or emergent spinal surgery within 6 months of cardiac stent placement, the risks of continuing (i.e. perioperative spinal hemorrhage resulting in severe disability or even death) versus stopping (i.e., acute stent thrombosis or even death) DAPT must be carefully weighed.[9] Here, we reviewed the literature regarding the feasibility and safety of performing urgent spinal surgery for patients on DAPT soon after DES placement utilizing a novel approach. The latter involves cessation of clopidogrel (5 days) and aspirin (3 days) preoperatively with postoperative reinstitution of aspirin (postoperative day 1) and clopidogrel (postoperative day 2).

MATERIALS AND METHODS

Important variables when considering surgery in a patient on DAPT for recent cardiac stent placement: (1) the urgency of the surgery, (2) the type of percutaneous cardiac intervention (PCI) (balloon angioplasty vs. stenting), (3) the stent type (drug-eluting vs. balloon mechanical stent), and (4) the PCI to noncardiac surgery time interval.[10] A thorough PubMed search yielded 510 papers on the topic. Critical variables studied included: outcomes of post-PCI patients undergoing emergent spine surgery while on DAPT, perioperative anticoagulation guidelines, and alternative drugs that lessen the risk of bleeding without increasing the risk of stent thrombosis. Summary of current evidence-based data regarding DAPT and timing of noncardiac surgery after PCI.

RESULTS

Guidelines for DAPT and timing of noncardiac surgery after PCI [Table 1]

The American College of Cardiology, American Heart Association, and European Society of Cardiology have relatively congruent guidelines regarding the necessity of DAPT for patients with acute coronary syndrome who have undergone PCI with the placement of DES.[4,7,9,10] However, the duration of treatment remains controversial. Most current guidelines require 6–12 months of DAPT with aspirin and clopidogrel after PCI revascularization, with continuation of aspirin recommended indefinitely [Table 1].
Table 1:

Summary of current evidence-based data regarding DAPT and timing of noncardiac surgery after PCI.

The guidelines currently recommend waiting at least 1 year before any noncardiac surgery after DES placement, to allow sufficient time for endothelialization.[10] Notably, the highest risk for stent thrombosis is within the first 6 weeks after stent placement.[9]

Urgent surgical treatment for cervical spondylotic myelopathy (CSM): indications and management

With rapidly progressing CSM, postponing surgery risks permanent severe disability. Treatment options for CSM include corpectomy and fusion, anterior cervical discectomy and fusion, posterior cervical decompression (with or without fusion), or any combination thereof.[8,13] Alternatively, if the patient is only minimally symptomatic, delaying surgery is a more reasonable option.[6] Summary of current evidence-based data regarding perioperative DAPT in major noncardiac surgery soon after PCI.

Perioperative management of DAPT for major noncardiac surgery soon after PCI [Table 2]

The Clopidogrel in Unstable Angina to Prevent Recurrent Events study and others concluded that patients on both aspirin and clopidogrel are more likely to have major bleeding events and bleeding complications with surgical interventions (3.4-fold) than those solely on aspirin (1.5-fold) [Table 2].[5,9] This bleeding risk is particularly concerning for spinal operations where any hemorrhage may result in catastrophic disability.
Table 2:

Summary of current evidence-based data regarding perioperative DAPT in major noncardiac surgery soon after PCI.

However, as the sudden cessation of DAPT can cause a reflex prothrombotic state possibly contributing to stent thrombosis, an antiplatelet “bridge” is recommended perioperatively.[9] Recommended bridging protocol.

Bridging protocol recommendations [Table 3]

No standard of care exists regarding perioperative management of patients with DES on DAPT undergoing spine surgery. Some recommend holding DAPT up to five half-lives before surgery and starting a bridging agent within 12 months of the PCI to minimize ischemic cardiac events.[9] When selecting a bridging agent, critical characteristics to consider include reversibility and a short half-life.[9] Bridging agents include GP IIb/IIIa receptor inhibitors which interfere with fibrinogen, oral irreversible P2Y12 receptor inhibitors, and thrombin protease-activated receptor inhibitors. Postoperatively, both aspirin and clopidogrel can be safely restarted on postoperative day 1 or 2 with loading doses [Table 3].[2] Interestingly, one study showed that bridging with low-molecular-weight heparin was linked to more major adverse cardiac and cerebrovascular events and bleeding complications versus remaining on DAPT perioperatively.[3]
Table 3:

Recommended bridging protocol.

Promise of cangrelor

Cangrelor, a reversible, intravenous P2Y12 inhibitor with rapid onset and return to baseline platelet function when discontinued may be considered as a new bridging agent [Figure 1].[1,11] Its safety and efficacy as a bridging agent have been established in the BRIDGE trial for patients undergoing coronary artery bypass grafting.[11] They found no excessive bleeding or significant increase in ischemic events.[11] The Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition trials demonstrated reduced stent thrombosis in the cangrelor group and comparable bleeding rates relative to the clopidogrel group.[1] Nonetheless, a drug application for the use of cangrelor in post-PCI patients as a bridging therapy in noncardiac surgeries was initially denied by the FDA in 2014; however, the drug was recently approved in 2016 for pretreatment in PCI patients only.[12]
Figure 1:

Illustration of the mechanism of action of the various groups of antiplatelet agents.

Illustration of the mechanism of action of the various groups of antiplatelet agents.

CONCLUSION

There is a great concern regarding the lack of clear guidelines for perioperative antiplatelet therapy for patients requiring urgent or emergent spine surgery within 6 months of PCI with DES implantation. We propose a novel protocol in which clopidogrel and aspirin are stopped 5 and 3 days before surgery, respectively, a reversible P2Y12 inhibitor such as cangrelor is used as bridging agent until the time of surgery, and postoperatively, aspirin and clopidogrel may be restarted on postoperative day 1 and 2, respectively.
  13 in total

1.  Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery.

Authors:  L Broad; T Lee; M Conroy; S Bolsin; N Orford; A Black; G Birdsey
Journal:  Br J Anaesth       Date:  2006-11-22       Impact factor: 9.166

2.  Cangrelor in patients undergoing cardiac surgery: the BRIDGE study.

Authors:  Michele D Voeltz; Steven V Manoukian
Journal:  Expert Rev Cardiovasc Ther       Date:  2013-07

3.  2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Glenn N Levine; Eric R Bates; John A Bittl; Ralph G Brindis; Stephan D Fihn; Lee A Fleisher; Christopher B Granger; Richard A Lange; Michael J Mack; Laura Mauri; Roxana Mehran; Debabrata Mukherjee; L Kristin Newby; Patrick T O'Gara; Marc S Sabatine; Peter K Smith; Sidney C Smith; Jonathan L Halperin; Glenn N Levine; Sana M Al-Khatib; Kim K Birtcher; Biykem Bozkurt; Ralph G Brindis; Joaquin E Cigarroa; Lesley H Curtis; Lee A Fleisher; Federico Gentile; Samuel Gidding; Mark A Hlatky; John S Ikonomidis; José A Joglar; Susan J Pressler; Duminda N Wijeysundera
Journal:  J Thorac Cardiovasc Surg       Date:  2016-11       Impact factor: 5.209

Review 4.  The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention.

Authors:  Sandeep Singla; Rajesh Sachdeva; Barry F Uretsky
Journal:  J Am Coll Cardiol       Date:  2012-10-17       Impact factor: 24.094

Review 5.  Cangrelor: a novel intravenous antiplatelet agent with a questionable future.

Authors:  Laura H Waite; Yvonne L Phan; Sarah A Spinler
Journal:  Pharmacotherapy       Date:  2014-08-13       Impact factor: 4.705

6.  Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery.

Authors:  D Capodanno; G Musumeci; C Lettieri; U Limbruno; M Senni; G Guagliumi; O Valsecchi; D J Angiolillo; R Rossini
Journal:  Thromb Haemost       Date:  2015-05-28       Impact factor: 5.249

Review 7.  Perioperative management of a patient with recently placed drug-eluting stents requiring urgent spinal surgery.

Authors:  Eira Roth; Chad Purnell; Olga Shabalov; Diego Moguillansky; Caridad A Hernandez; Michael Elnicki
Journal:  J Gen Intern Med       Date:  2012-01-31       Impact factor: 5.128

Review 8.  Hybrid Decompression Technique Versus Anterior Cervical Corpectomy and Fusion for Treating Multilevel Cervical Spondylotic Myelopathy: Which One Is Better?

Authors:  Jia-Ming Liu; Hong-Wei Peng; Zhi-Li Liu; Xin-Hua Long; Yan-Qing Yu; Shan-Hu Huang
Journal:  World Neurosurg       Date:  2015-09-02       Impact factor: 2.104

9.  Perioperative management of antiplatelet therapy in patients with drug-eluting stents.

Authors:  G Dimitrova; D B Tulman; S D Bergese
Journal:  HSR Proc Intensive Care Cardiovasc Anesth       Date:  2012

Review 10.  Anterior cervical discectomy and fusion versus anterior cervical corpectomy and fusion in multilevel cervical spondylotic myelopathy: A meta-analysis.

Authors:  Tao Wang; Hui Wang; Sen Liu; Huang-Da An; Huan Liu; Wen-Yuan Ding
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.